Venom, translated.

The headline writes itself: there is snake venom in your face cream. The reality is more elegant. The active is almost never venom — it is a synthetic peptide that copies one short fragment of a venom protein, manufactured to be safe, stable and consistent. The most famous is Syn-Ake, developed by the Swiss firm Pentapharm. It mimics Waglerin-1, a polypeptide from the venom of the temple viper, Tropidolaemus wagleri.

Waglerin-1 is only three amino acids long. It works as an antagonist at the muscle nicotinic acetylcholine receptor (nAChR), blocking sodium uptake at the post-synaptic membrane and so dampening muscle contraction — the same target, by a different route, as botulinum toxin. Applied to skin, the peptide produces a transient softening of expression lines. The effect is real but temporary: it must be reapplied.

The category is bigger than one molecule. Peptide actives — venom-mimetic, plant-derived and lab-designed — are among the fastest-growing in skincare. Estimates of market size vary by how the segment is drawn, but every serious forecast points the same way: up.

Mechanistic detail is drawn from peer-reviewed pharmacology of viper-venom peptides and the cosmeceutical literature, principally a 2025 review in Applied Sciences. Market figures are vendor estimates that differ by segment definition; we show two named series rather than a single headline number. We do not claim that topical peptides equal injectable neurotoxins — the sources are explicit that the effect is transient and milder.